FilariasisPhase 1NCT03383614
Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside
A Phase 1 study of Filariasis, run by Drugs for Neglected Diseases at 1 site in United Kingdom.
Trial summary
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Filariasis
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 14 Nov 2017to 15 Oct 2018
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male, Caucasian volunteers, deemed healthy based on a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.
- 18 to 45 years of age.
- Normal body weight (BMI; Quetelet index) in the range 18 to 30.1 kg/m2 at screening.
- Blood pressure and heart rate in the supine position prior to randomisation must be within the ranges 90-140 mm Hg systolic, 60-90 mm Hg diastolic; heart rate 45-100 beats/min.
- Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.
- Willingness to give written consent to participate, after reading the information and consent form, and after having the opportunity to discuss the trial with the Investigator or his delegate.
- Willingness to give written consent to have data entered into the Overvolunteering Prevention System.
- Willingness to agree to the contraceptive requirements of the study from the first dose until 120 days after the last dose of study medication.
Who cannot join
- Administration of a licensed or unlicensed medicinal product as part of another clinical trial within the 3 months before, or within 5 half-lives of, their first dose of study medication, whichever is longer, or is currently in the follow-up period for any clinical trial.
- Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness or history of chronic illness (such as diabetes mellitus or other abnormalities of glucose homeostasis) sufficient to invalidate the subject's participation in the trial or make it unnecessarily hazardous.
- Past surgery (e.g., stomach bypass) or medical condition that might affect absorption of study drug taken orally.
- Presence of abnormal physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject.
- Loss of more than 400 mL of blood within 3 months before admission.
- Clinically relevant history of vital organ disease or other disease of an organ or the central nervous system.
Show all 32Show fewer
- Current or previous medical or psychiatric disorder, condition or history of such (e.g., seizures) that, in the opinion of the Investigator or the Sponsor, would increase the risk associated with study participation, or impair the subject's ability to participate or complete this study.
- Positive test for hepatitis B, hepatitis C or HIV.
- Febrile illness within 1 week before the first dose of study medication.
- History of severe allergy, non-allergic drug reactions, severe adverse reaction to any drug, or multiple drug allergies.
- Subjects with hypersensitivity to any ingredient of the study medication, including the active ingredient, emodepside.
- Presence or history of drug or alcohol abuse in the last 10 years, or intake of more than 21 units of alcohol weekly.
- Regular daily consumption of more than one liter of xanthine-containing beverages.
- Regular daily consumption of more than 5 cigarettes daily, or use more than 3 grams (1/8 ounce) of tobacco.
- Use of a prescription medicine during the 28 days before the first dose of study medication or use of an over-the-counter medicine (with exception of acetaminophen [paracetamol]), during the 7 days before the first dose of study medication.
- Use of dietary supplements or herbal remedies (such as St John's Wort) that are known to be inducers or inhibitors of CYP3A4, or other co-medications known to be relevant substrates of CYP3A4, during the 28 days before the first dose of study medication (see list in the Study Procedures Manual).
- Use of dietary supplements or herbal remedies (such as St John's Wort) that are known to be strong inhibitors of P-gp, or other co-medications known to be relevant substrates of P-gp, during the 28 days before the first dose of study medication (see list in the Study Procedures Manual).
- Relevant pathological abnormalities in the ECG at screening, such as a second or third-degree atrioventricular (AV) block or prolongation of the QRS complex over 120 msec or QTc-interval over 450 msec (corrected using Bazett's [QTcB] or Fridericia's [QTcF] formulae).
- Evidence of drug abuse (via urine testing) at the screening assessment or admission to the ward.
- Use of excluded therapies that may impact on the interpretation of study results in the opinion of the Investigator or Sponsor.
- Objection by General Practitioner (GP) to subject entering trial.
- History of residing for 6 or more continuous months, within the last 3 years, in regions with endemic parasitic infections as determined by the Investigator.
- Possibility that subject will not cooperate with the requirements of the protocol.
- No contact lenses wear within 1 month before dosing. Wearing contact lenses is not permitted during the study.
- Any ocular disorder for which topical ocular therapy is currently or chronically prescribed, including inflammatory eye disease (dry eye allergic conjunctivitis [seasonal allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis], uveitis and glaucoma).
- Past history of ocular disease requiring ongoing treatment.
- Past ocular surgery including laser or other refractive corneal surgery.
- Evidence of eye irritation, visual difficulties, corneal opacity, ocular surface (corneal or conjunctival damage, with or without ocular symptoms).
- Evidence of narrow anterior chamber angles causing increased risk of acute glaucoma.
- Evidence of ocular media opacity including lens opacity/vitreous opacities.
- Evidence of retinal or optic nerve pathology.
- Evidence of pronounced colour blindness, as indicated by an Ishihara score of 9/13 or below.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Hammersmith Medicines Research Limited
London, NW10 7EW
About this study
Official title: A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
Read the detailed description
There is an urgent need for a macrofilaricidal drug, killing or sterilizing permanently O. volvulus adult worms, which could be used in individual case management and, after appropriate testing, as an alternative drug to ivermectin in Mass Drug Administration (MDA) programs. Emodepside is a promising candidate to kill the adult and sexually mature O. volvulus as explained below. Emodepside was shown to be macrofilaricidal against a variety of filarial nematodes and is a registered drug for animal health, commercialized by Bayer AG under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril).
A first-in-human (FIH) double-blind, placebo-controlled study of single ascending doses of emodepside in healthy Caucasian men has been conducted and the preliminary results are favourable, supporting continuation of the Phase I development program. In the present repeat dose study, PK as well as safety and tolerability of the liquid service formulation of emodepside, given over 10 days, will be tested.
- Conditions
- Filariasis
- Being tested
- LSF emodepside (BAY 44-4400) or matching placebo
- Medical subject headings
- Filariasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LSF emodepside (BAY 44-4400) or matching placeboDrug
Emodepside administered as an LSF oral solution (1mg/mL)
| Study group | Role | What they receive |
|---|---|---|
| cohort 1 (8 subjects) | Experimental | 6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo Receives: Drug: LSF emodepside (BAY 44-4400) or matching placebo |
| cohort 2 (8 subjects) | Experimental | 6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo Receives: Drug: LSF emodepside (BAY 44-4400) or matching placebo |
| cohort 3 (8 subjects) | Experimental | 6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo Receives: Drug: LSF emodepside (BAY 44-4400) or matching placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events
Death, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs).
Measured: up to 120 days
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Adverse Event Severity
Number of subjects with a TEAE, by highest level of severity.
Measured: Up to 120 days
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Vital Signs Findings
Vital signs included heart rate, systolic and diastolic blood pressure and temperature.
Measured: up to 120 days
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With 12-lead Electrocardiogram Findings
The following variables were recorded in 12-lead ECGs: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.
Measured: up to 30 days
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Clinical Laboratory Tests Findings
Clinical laboratory parameters included clinical chemistry, hematology, coagulation and urinalysis.
Measured: up to 120 days
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Ophthalmology Assessment Findings
Ophthalmological examinations at Screening Visit 2 and Day 10 were done at a specialist eye hospital by a Consultant Ophthalmologist, or their assistant. Examinations included: ocular symptoms and history, autorefraction, best correct visual acuity, colour vision, Amsler grid, ocular alignment and motility, confrontation visual field, slit-lamp, measurement of intraocular pressure and an optical coherence tomography test.
Measured: up to 10 days
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Physical Examination Findings
Abnormal or clinically significant physical examination findings during the study or reported as an adverse event.
Measured: up to 120 days
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Neurological Examination Findings
Abnormal or clinically significant neurological examination findings during the study or reported as an adverse event.
Measured: up to 120 days
Secondary outcomes (40)
Geometric Mean Emodepside Plasma Pharmacokinetic Concentration-Time Data During the Repeated Dosing Period
Summary of geometric mean emodepside plasma pharmacokinetic concentration-time data (ng/mL) during the repeated dosing period (Days 0-9) in healthy men.
Subjects in the 10 mg emodepside BID dosing group had twice-daily doses on Days 0-8 and a single dose on the morning of Day 9. Therefore, the Day 9, 24 h post-dose value was not comparable to the previous value in that dosing group.
Measured: From Day 1, pre-dose to Day 9, 24 hours post-dose
The AUClast of Emodepside in Plasma
Summary of AUClast of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration.
PK=pharmacokinetic. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUClast in plasma after the last dose (Day 9)
The AUClast/D of Emodepside in Plasma
Summary of AUClast/D of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast/D: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUClast /D in plasma after the last dose (Day 9)
The AUClast,Norm of Emodepside in Plasma
Summary of AUClast,norm of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUClast,norm: the area under the concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUClast,norm in plasma after the last (Day 9) dose
The AUC12 of Emodepside in Plasma
Summary of AUC12 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12: the area under the concentration-time curve from time zero (pre-dose) to 12h.
Note: AUC12 was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUC12 in plasma after the first (Day 0) and last (Day 9) dose
The AUC12/D of Emodepside in Plasma
Summary of AUC12/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC12/D: the area under the concentration-time curve from time zero (pre-dose) to 12h, corrected for dose.
Note: AUC12/D was collected only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUC12/D in plasma after the first (Day 0) and last (Day 9) dose
The AUC12,Norm of Emodepside in Plasma
Summary of AUC12,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC12,norm: the area under the concentration-time curve from time zero (pre-dose) to 12 h corrected by dose and body weight.
Note: AUC12,norm was calculated only in Cohort 3. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUC12,norm in plasma after the first (Day 0) and last (Day 9) dose
The AUC24 of Emodepside in Plasma
Summary of AUC24 of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24: the area under the concentration-time curve from time zero (pre-dose) to 24 h.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUC24 in plasma after the first (Day 0) and last (Day 9) dose
The AUC24/D of Emodepside in Plasma
Summary of AUC24/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
AUC24/D: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUC24/D in plasma after the first (Day 0) and last (Day 9) dose
The AUC24,Norm of Emodepside in Plasma
Summary of AUC24,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120h (Day 14) after the morning dose.
AUC24,norm: the area under the concentration-time curve from time zero (pre-dose) to 24h corrected by dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: AUC24,norm in plasma at Day 0 and Day 9
The Cmax of Emodepside in Plasma
Summary of Cmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: Cmax in plasma after the first (Day 0) and last (Day 9) dose
The Cmax/D of Emodepside in Plasma
Summary of Cmax/D of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax/D: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: Cmax/D in plasma after the first (Day 0) and last (Day 9) dose
The Cmax,Norm of Emodepside in Plasma
Summary of Cmax,norm of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Cmax,norm: the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data, corrected for dose and body weight.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: Cmax,norm in plasma after the first (Day 0) and last (Day 9) dose
The Ctrough of Emodepside in Plasma
Summary of Ctrough (log-transformed) of emodepside after last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Ctrough: trough plasma concentration (measured concentration at the end of a dosing interval on Day 9 [taken directly before next administration]) obtained directly from the concentration-time data.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: Ctrough in plasma after the last (Day 9) dose
The Tmax of Emodepside in Plasma
Summary of tmax of emodepside after the first (Day 0) and last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose. Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
tmax: the time at which Cmax was apparent, identified by inspection of the drug concentration vs. time data.
Measured: tmax in plasma after the first (Day 0) and last (Day 9) dose
The t1/2 of Emodepside in Plasma
Summary of t1/2 of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2: terminal half-life. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: t1/2 in plasma after the last (Day 9) dose
The t1/2,(0-24) of Emodepside in Plasma
Summary of t1/2,(0-24) of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
t1/2,(0-24): half-life calculated from the terminal slope of the log concentration-time (0-24h) curve.
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: t1/2,(0-24) in plasma after the last (Day 9) dose
The λz of Emodepside in Plasma
Summary of λz of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
λz: terminal rate constant. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: λz in plasma after the last (Day 9) dose
The CLss/F of Emodepside in Plasma
Summary of CLss/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
CLss/F: apparent total clearance from plasma on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: CLss/F in plasma after the last (Day 9) dose
The Vz/F of Emodepside in Plasma
Summary of Vz/F of emodepside after the last (Day 9) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 9 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 36 (Day 10), 48 (Day 11), 72 (Day 12), 96 (Day 13) and 120 h (Day 14) after the morning dose.
Vz/F: apparent volume of distribution on Day 9. The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: Vz/F in plasma after the last (Day 9) dose
The MRTlast of Emodepside in Plasma
Summary of MRTlast of emodepside after the first (Day 0) dose for 10-day oral treatment courses in healthy men: PK parameter population.
Data on Day 0 was collected at the following time points: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 15 h after the morning dose.
MRTlast: mean residence time from time zero (pre-dose) to the time of last quantifiable concentration (measurable up to 24h after dosing on Day 0).
The geometric coefficient of variation is the between-subject coefficient of variation (%CVb).
Measured: MRTlast in plasma after the first (Day 0) dose
The Rac(AUC12) of Emodepside in Plasma
Summary of emodepside plasma Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC12): accumulation ratio calculated from AUC12, where AUC12 is the area under the concentration-time curve from time zero (pre-dose) to 12h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).
Note: Rac(AUC12) was calculated only in Cohort 3.
Measured: Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9)
The Rac(AUC24) of Emodepside in Plasma
Summary of emodepside plasma Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(AUC24): accumulation ratio calculated from AUC24, where AUC24 is the area under the concentration-time curve from time zero (pre-dose) to 24h.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).
Measured: Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9)
The Rac(Cmax) of Emodepside in Plasma
Summary of emodepside plasma Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9): PK parameter population.
Rac(Cmax): accumulation ratio calculated from Cmax, where Cmax is the observed maximum plasma concentration measured in a subject after dosing identified by inspection of the drug concentration vs. time data.
Note: measure of dispersion is 'percentage coefficient of variation' (the between-subject coefficient of variation [%CVb]).
Measured: Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9)
Mean Glucose Concentration at Day -1
Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.
Measured: Mean glucose at Day -1 after repeated once or twice daily dosing
Mean Glucose Concentration at Day 0
Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.
Measured: Mean glucose after repeated once or twice daily dosing for up to 10 days
Mean Glucose Concentration at Day 9
Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.
Measured: Mean glucose at Day 9 after repeated once or twice daily dosing
Mean Glucose Concentration at Day 30
Mean glucose concentrations (mmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.
Measured: Mean glucose at Day 30 after repeated once or twice daily dosing
Mean Insulin Concentration at Day -1
Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day -1.
Measured: Mean insulin concentration at Day-1 after repeated once or twice daily dosing
Mean Insulin Concentration at Day 0
Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 0.
Baseline=predose on Day 0.
Measured: Mean insulin concentration at Day 0 after repeated once or twice daily dosing
Mean Insulin Concentration at Day 9
Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 9.
Measured: Mean insulin concentration at Day 9 after repeated once or twice daily dosing
Mean Insulin Concentration at Day 30
Mean insulin concentration (pmol/L) after repeated once or twice daily dosing with up to 10 mg emodepside or placebo at Day 30.
Measured: Mean insulin concentration at Day 30 after repeated once or twice daily dosing
Mean Serum Glucose Concentration at Day -2
Oral glucose tolerance test: mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.
Measured: Mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Glucose Concentration at Day 1
Oral glucose tolerance test: mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.
Measured: Mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Glucose Concentration at Day 8
Oral glucose tolerance test: mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.
Measured: Mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Glucose Concentration at Day 120
Oral glucose tolerance test: mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)
Measured: Mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day -2
Oral glucose tolerance test: mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.
Measured: Mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day 1
Oral glucose tolerance test: mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.
Measured: Mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day 8
Oral glucose tolerance test: mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day.
Measured: Mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day 120
Oral glucose tolerance test: mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution, in subjects receiving repeated doses of emodepside or placebo for 10 days (Days 0-9).
Baseline=pre-glucose intake on each respective day. Note: At Day 120, serum glucose concentration was only measured in Cohort 3 (10 mg BID)
Measured: Mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2017
- Study start14 Nov 2017
- Primary completion15 Oct 2018
- Study completion15 Oct 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for FilariasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- Drugs for Neglected Diseases
- Sponsor type
- University, hospital or other
- Collaborators
- Bayer, Bill and Melinda Gates Foundation
- Responsible party
- Sponsor
- Investigators
- Jeremy Dennison, PhD MBChB, Principal investigator, Hammersmith Medicines Research Limited
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03383614
- Sponsor's protocol ID
- DNDI-EMO-02
- Other IDs
- 2017-003020-75, 2017
- Status last verified
- Apr 2020
- First submitted
- 29 Nov 2017
- Last updated
- 15 Apr 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects
- ClinicalTrials.gov ID
- NCT03383614
- Acronym / sponsor ID
- DNDI-EMO-02
- Conditions
- Filariasis
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- Drugs for Neglected DiseasesUniversity, hospital or other
- Collaborators
- Bayer, Bill and Melinda Gates Foundation
- Study start
- 14 Nov 2017 (actual)
- Primary completion
- 15 Oct 2018 (actual)
- Study completion
- 15 Oct 2018 (actual)
- First posted
- 26 Dec 2017 (actual)
- Results
- Posted 15 Apr 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.
Detailed description
There is an urgent need for a macrofilaricidal drug, killing or sterilizing permanently O. volvulus adult worms, which could be used in individual case management and, after appropriate testing, as an alternative drug to ivermectin in Mass Drug Administration (MDA) programs. Emodepside is a promising candidate to kill the adult and sexually mature O. volvulus as explained below. Emodepside was shown to be macrofilaricidal against a variety of filarial nematodes and is a registered drug for animal health, commercialized by Bayer AG under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril).
A first-in-human (FIH) double-blind, placebo-controlled study of single ascending doses of emodepside in healthy Caucasian men has been conducted and the preliminary results are favourable, supporting continuation of the Phase I development program. In the present repeat dose study, PK as well as safety and tolerability of the liquid service formulation of emodepside, given over 10 days, will be tested.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| cohort 1 (8 subjects) | Experimental | Drug: LSF emodepside (BAY 44-4400) or matching placebo6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo |
| cohort 2 (8 subjects) | Experimental | Drug: LSF emodepside (BAY 44-4400) or matching placebo6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo |
| cohort 3 (8 subjects) | Experimental | Drug: LSF emodepside (BAY 44-4400) or matching placebo6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Male, Caucasian volunteers, deemed healthy based on a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.
- 18 to 45 years of age.
- Normal body weight (BMI; Quetelet index) in the range 18 to 30.1 kg/m2 at screening.
- Blood pressure and heart rate in the supine position prior to randomisation must be within the ranges 90-140 mm Hg systolic, 60-90 mm Hg diastolic; heart rate 45-100 beats/min.
- Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.
Key exclusion criteria (32 listed)
- Administration of a licensed or unlicensed medicinal product as part of another clinical trial within the 3 months before, or within 5 half-lives of, their first dose of study medication, whichever is longer, or is currently in the follow-up period for any clinical trial.
- Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness or history of chronic illness (such as diabetes mellitus or other abnormalities of glucose homeostasis) sufficient to invalidate the subject's participation in the trial or make it unnecessarily hazardous.
- Past surgery (e.g., stomach bypass) or medical condition that might affect absorption of study drug taken orally.
- Presence of abnormal physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject.
- Loss of more than 400 mL of blood within 3 months before admission.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LSF emodepside (BAY 44-4400) or matching placeboEmodepside administered as an LSF oral solution (1mg/mL) | Drug | cohort 1 (8 subjects), cohort 2 (8 subjects), cohort 3 (8 subjects) |
Primary outcome
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events
Time frame: up to 120 days
Death, serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs).
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Adverse Event Severity
Time frame: Up to 120 days
Number of subjects with a TEAE, by highest level of severity.
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Vital Signs Findings
Time frame: up to 120 days
Vital signs included heart rate, systolic and diastolic blood pressure and temperature.
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With 12-lead Electrocardiogram Findings
Time frame: up to 30 days
The following variables were recorded in 12-lead ECGs: ventricular rate, PR interval, QRS interval, QTcB and QTcF interval.
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Clinical Laboratory Tests Findings
Time frame: up to 120 days
Clinical laboratory parameters included clinical chemistry, hematology, coagulation and urinalysis.
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Ophthalmology Assessment Findings
Time frame: up to 10 days
Ophthalmological examinations at Screening Visit 2 and Day 10 were done at a specialist eye hospital by a Consultant Ophthalmologist, or their assistant. Examinations included: ocular symptoms and history, autorefraction, best correct visual acuity, colour vision, Amsler grid, ocular alignment and motility, confrontation visual field, slit-lamp, measurement of intraocular pressure and an optical coherence tomography test.
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Physical Examination Findings
Time frame: up to 120 days
Abnormal or clinically significant physical examination findings during the study or reported as an adverse event.
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Neurological Examination Findings
Time frame: up to 120 days
Abnormal or clinically significant neurological examination findings during the study or reported as an adverse event.
40 secondary outcomes
Geometric Mean Emodepside Plasma Pharmacokinetic Concentration-Time Data During the Repeated Dosing Period
Time frame: From Day 1, pre-dose to Day 9, 24 hours post-dose
The AUClast of Emodepside in Plasma
Time frame: AUClast in plasma after the last dose (Day 9)
The AUClast/D of Emodepside in Plasma
Time frame: AUClast /D in plasma after the last dose (Day 9)
The AUClast,Norm of Emodepside in Plasma
Time frame: AUClast,norm in plasma after the last (Day 9) dose
The AUC12 of Emodepside in Plasma
Time frame: AUC12 in plasma after the first (Day 0) and last (Day 9) dose
The AUC12/D of Emodepside in Plasma
Time frame: AUC12/D in plasma after the first (Day 0) and last (Day 9) dose
The AUC12,Norm of Emodepside in Plasma
Time frame: AUC12,norm in plasma after the first (Day 0) and last (Day 9) dose
The AUC24 of Emodepside in Plasma
Time frame: AUC24 in plasma after the first (Day 0) and last (Day 9) dose
The AUC24/D of Emodepside in Plasma
Time frame: AUC24/D in plasma after the first (Day 0) and last (Day 9) dose
The AUC24,Norm of Emodepside in Plasma
Time frame: AUC24,norm in plasma at Day 0 and Day 9
The Cmax of Emodepside in Plasma
Time frame: Cmax in plasma after the first (Day 0) and last (Day 9) dose
The Cmax/D of Emodepside in Plasma
Time frame: Cmax/D in plasma after the first (Day 0) and last (Day 9) dose
The Cmax,Norm of Emodepside in Plasma
Time frame: Cmax,norm in plasma after the first (Day 0) and last (Day 9) dose
The Ctrough of Emodepside in Plasma
Time frame: Ctrough in plasma after the last (Day 9) dose
The Tmax of Emodepside in Plasma
Time frame: tmax in plasma after the first (Day 0) and last (Day 9) dose
The t1/2 of Emodepside in Plasma
Time frame: t1/2 in plasma after the last (Day 9) dose
The t1/2,(0-24) of Emodepside in Plasma
Time frame: t1/2,(0-24) in plasma after the last (Day 9) dose
The λz of Emodepside in Plasma
Time frame: λz in plasma after the last (Day 9) dose
The CLss/F of Emodepside in Plasma
Time frame: CLss/F in plasma after the last (Day 9) dose
The Vz/F of Emodepside in Plasma
Time frame: Vz/F in plasma after the last (Day 9) dose
The MRTlast of Emodepside in Plasma
Time frame: MRTlast in plasma after the first (Day 0) dose
The Rac(AUC12) of Emodepside in Plasma
Time frame: Rac(AUC12) after 10 days' repeated doses of 10 mg emodepside (Day 9)
The Rac(AUC24) of Emodepside in Plasma
Time frame: Rac(AUC24) after 10 days' repeated doses of 10 mg emodepside (Day 9)
The Rac(Cmax) of Emodepside in Plasma
Time frame: Rac(Cmax) after 10 days' repeated doses of 10 mg emodepside (Day 9)
Mean Glucose Concentration at Day -1
Time frame: Mean glucose at Day -1 after repeated once or twice daily dosing
Mean Glucose Concentration at Day 0
Time frame: Mean glucose after repeated once or twice daily dosing for up to 10 days
Mean Glucose Concentration at Day 9
Time frame: Mean glucose at Day 9 after repeated once or twice daily dosing
Mean Glucose Concentration at Day 30
Time frame: Mean glucose at Day 30 after repeated once or twice daily dosing
Mean Insulin Concentration at Day -1
Time frame: Mean insulin concentration at Day-1 after repeated once or twice daily dosing
Mean Insulin Concentration at Day 0
Time frame: Mean insulin concentration at Day 0 after repeated once or twice daily dosing
Mean Insulin Concentration at Day 9
Time frame: Mean insulin concentration at Day 9 after repeated once or twice daily dosing
Mean Insulin Concentration at Day 30
Time frame: Mean insulin concentration at Day 30 after repeated once or twice daily dosing
Mean Serum Glucose Concentration at Day -2
Time frame: Mean serum glucose concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Glucose Concentration at Day 1
Time frame: Mean serum glucose concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Glucose Concentration at Day 8
Time frame: Mean serum glucose concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Glucose Concentration at Day 120
Time frame: Mean serum glucose concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day -2
Time frame: Mean serum insulin concentration at Day -2, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day 1
Time frame: Mean serum insulin concentration at Day 1, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day 8
Time frame: Mean serum insulin concentration at Day 8, before and up to 4 hours after intake of a high-glucose solution
Mean Serum Insulin Concentration at Day 120
Time frame: Mean serum insulin concentration at Day 120, before and up to 4 hours after intake of a high-glucose solution
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Filariasis
Active, not recruitingObservational study
Host Response to Infection and Treatment in Filarial Diseases
Filariasis, Helminthiasis
RecruitingPhase 3
Better Options for Lymphatic Filariasis Treatment
Lymphatic Filariasis, Scabies
Recruiting
Expanding Access to Preventive Chemotherapy Among Mobile and Migrant Populations
Onchocerciasis (River Blindness), Schistosomiasis
Not yet recruiting
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
RecruitingObservational study
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Dengue, Chikungunya
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jeremy Dennison, PhD MBChB principal investigator
Hammersmith Medicines Research Limited
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study of Filariasis, run by Drugs for Neglected Diseases at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 32 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 15 Apr 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Tolerability of Emodepside After Multiple Doses as Measured by Number of Participants With Adverse Events (time frame: up to 120 days). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2020.